MindRank announces first patient dosed in Phase III trial of AI-designed oral GLP-1 receptor agonist MDR-001

MindRank has dosed the first patient in the Phase III MOBILE trial of MDR-001, an AI-designed oral GLP-1 receptor agonist for obesity and type 2 diabetes. The randomized, double-blind, placebo-controlled study is planned for about 750 patients across 50 clinical centers in China.

MindRank announced that the first patient has been dosed in the Phase III clinical trial of MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist intended for obesity and type 2 diabetes. The trial, called MOBILE, is described as a multicenter, randomized, double-blind, placebo-controlled study in China. MindRank says the program used its proprietary AI platforms to discover and optimize the molecule. The company reported that a Phase IIb trial showed clinically meaningful efficacy, favorable tolerability, and improvements in cardiometabolic parameters. Key details: - The MOBILE Phase III trial is planned to include approximately 750 patients across about 50 clinical centers in China. - The study is led by Professor Linong Ji of Peking University People's Hospital and is randomized, double-blind, and placebo-controlled. - MindRank reports MDR-001 is a biased, selective oral GLP-1 receptor agonist discovered with its Molecule Pro™ AI platform and related tools such as PharmKG™ and Molecule Dance™. - The company states the program progressed from project start to U.S. IND clearance in 19 months and advanced to Phase III within roughly 4.5 years. - MindRank described Molecule Pro™ as an AI-driven platform that integrates computational chemistry, biology, and predictive modules for ADMET and off-target risk. Summary: Dosing the first patient moves MDR-001 into a large, late-stage trial intended to evaluate long-term efficacy and safety in people with obesity and type 2 diabetes. Timing for trial readouts or regulatory milestones was not specified and is undetermined at this time.